Semi-quantitative Measurement of a Specific Glycoform Using a DNA-tagged Antibody and Lectin Affinity Chromatography for Glyco-biomarker Development *

Ju Hee Lee, Chang Hee Cho, Sun Hee Kim, Jeong Gu Kang, Jong Shin Yoo, Chulhun L. Chang, Jeong‐Heon Ko, Yong-Sam Kim

Molecular & Cellular Proteomics · 2014 · 10 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Aberrant glycosylation-targeted disease biomarker development is based on cumulative evidence that certain glycoforms are mass-produced in a disease-specific manner. However, the development process has been hampered by the absence of an efficient validation method based on a sensitive and multiplexed platform. In particular, ELISA-based analytical tools are not adequate for this purpose, mainly because of the presence of a pair of N-glycans of IgG-type antibodies. To overcome the associated hurdles in this study, antibodies were tagged with oligonucleotides with T7 promoter and then allowed to form a complex with corresponding antigens. An antibody-bound specific glycoform was isolated by lectin chromatography and quantitatively measured on a DNA microarray chip following production of fluorescent RNA by T7-trascription. This tool ensured measurement of targeted glycoforms of multiple biomarkers with high sensitivity and multiplexity. This analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions. The results indicated that the tests using the multiplexed fuco-biomarkers provided improved discriminatory power between non- hepatocellular carcinoma and hepatocellular carcinoma subjects compared with the alpha-fetoprotein level or fuco-alpha-fetoprotein test alone. The developed method is expected to facilitate the validation of disease-specific glycan biomarker candidates. Aberrant glycosylation-targeted disease biomarker development is based on cumulative evidence that certain glycoforms are mass-produced in a disease-specific manner. However, the development process has been hampered by the absence of an efficient validation method based on a sensitive and multiplexed platform. In particular, ELISA-based analytical tools are not adequate for this purpose, mainly because of the presence of a pair of N-glycans of IgG-type antibodies. To overcome the associated hurdles in this study, antibodies were tagged with oligonucleotides with T7 promoter and then allowed to form a complex with corresponding antigens. An antibody-bound specific glycoform was isolated by lectin chromatography and quantitatively measured on a DNA microarray chip following production of fluorescent RNA by T7-trascription. This tool ensured measurement of targeted glycoforms of multiple biomarkers with high sensitivity and multiplexity. This analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions. The results indicated that the tests using the multiplexed fuco-biomarkers provided improved discriminatory power between non- hepatocellular carcinoma and hepatocellular carcinoma subjects compared with the alpha-fetoprotein level or fuco-alpha-fetoprotein test alone. The developed method is expected to facilitate the validation of disease-specific glycan biomarker candidates. Protein-attached glycans are bio-synthesized by a subset of glycosyltransferases mostly located in the endoplasmic reticulum and the Golgi apparatus, and play various functional roles at molecular and cellular levels including molecular interactions, stability, immune function, adhesion, etc. However, cumulative lines of evidence indicate that aberrant glycosylation is associated with various diseases including cancer (1Christiansen M.N. Chik J. Lee L. Anugraham M. Abrahams J.L. Packer N.H. Cell surface protein glycosylation in cancer.Proteomics. 2014; 14: 525-546Crossref PubMed Scopus (370) Google Scholar), either by influencing the functionality of proteins and cells or as nonfunctional participants (2Kim Y.S. Hwang S.Y. Kang H.Y. Sohn H. Oh S. Kim J.Y. Kim C.H. Jeon J.H. Lee J.M. Kang H.A. Miyoshi E. Taniguchi N. Yoo H.S. Ko J.H. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1.Mol. Cell. Proteomics. 2008; 7: 1-14Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar, 3Häuselmann I. Borsig L. Altered tumor-cell glycosylation promotes metastasis.Front. Oncol. 2014; 4: 28Crossref PubMed Scopus (257) Google Scholar, 4Meany D.L. Chan D.W. Aberrant glycosylation associated with enzymes as cancer biomarkers.Clin. Proteomics. 2011; 8: 7Crossref PubMed Scopus (184) Google Scholar). Causal roles of aberrant glycosylation have been widely investigated in the development and progression of diseases, and significant progress has been made in the realm of cancer research (5Kim Y.S. Yoo H.S. Ko J.H. Implication of aberrant glycosylation in cancer and use of lectin for cancer biomarker discovery.Protein Pept. Lett. 2009; 16: 499-507Crossref PubMed Scopus (34) Google Scholar). For these reasons, glycoproteins carrying aberrant glycans have been targets for the development of in vitro diagnostics (6Adamczyk B. Tharmalingam T. Rudd P.M. Glycans as cancer biomarkers.Biochim. Biophys. Acta. 2012; 1820: 1347-1353Crossref PubMed Scopus (382) Google Scholar). Alpha feto protein (AFP) -L3, a fucoform of AFP that is retained by the Lens culinaris lectin (LCA), is an extensively proven disease biomarker (7Cheng J. Wang W. Zhang Y. Liu X. Li M. Wu Z. Liu Z. Lv Y. Wang B. Prognostic role of pretreatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.PLOS One. 2014; 9: e87011Crossref PubMed Scopus (48) Google Scholar). AFP is frequently overexpressed in hepatic carcinoma cells and thus exists at high concentrations in blood of patients with hepatocellular carcinoma (HCC) (8Xia Y. Yan Z.L. Xi T. Wang K. Li J. Shi L.H. Wu M.C. Shen F. A case-control study of correlation between preoperative serum AFP and recurrence of hepatocellular carcinoma after curative hepatectomy.Hepatogastroenterol. 2012; 59: 2248-2254PubMed Google Scholar). However, the onco-fetal protein is reported to surge even under non-tumor disease conditions such as inflammation or abnormal pregnancy (9Potapovich A.I. Pastore S. Kostyuk V.A. Lulli D. Mariani V. De Luca C. Dudich E.I. Korkina L.G. alpha-Fetoprotein as a modulator of the pro-inflammatory response of human keratinocytes.Br. J. Pharmacol. 2009; 158: 1236-1247Crossref PubMed Scopus (14) Google Scholar, 10Androutsopoulos G. Gkogkos P. Decavalas G. Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome.Int. J. Endocrinol. Metab. 2013; 11: 102-106Crossref PubMed Scopus (27) Google Scholar). This indicates a limited utility of AFP because of low specificity for prediction or diagnosis of HCC. Because it has been reported that the ratio of AFP-L3 to total AFP could be highly specific for HCC, AFP-L3 has been a preferred HCC biomarker to AFP levels and extensive investigations culminated in FDA-approval of an AFP-L3 lab test to determine the risk of developing liver cancer in patients with chronic liver disease (11Shiraki K. Takase K. Tameda Y. M. Y. T. A clinical study of alpha-fetoprotein as an of hepatocellular carcinoma in the of PubMed Google Scholar). glycan of a with cancer including and have been reported in terms of with cancer D. and as a biomarker for Acta. PubMed Scopus Google Scholar, C. D. M. with 2013; PubMed Scopus Google Scholar). Because of the potential in the clinical use of the glycan the to in glycan and to use as cancer biomarkers is thus and this has to be to cancer and Ko J.H. Kim Y.S. and of using aberrant glycosylation as biomarkers for in 2011; PubMed Scopus Google Scholar). However, the development of an aberrant cancer biomarker has been hampered by the absence of an analytical tool to the protein glycan in a sensitive and manner. is the preferred for diagnostic it is to proteins of or levels at biomarkers are to N. biomarker and the and to clinical PubMed Scopus Google Scholar, The human and diagnostic Cell. Proteomics. Full Text Full Text PDF PubMed Scopus Google Scholar). the high and high of proteins in it is to a glycoform of multiple glycoproteins with levels in A and a lectin is an analytical sensitivity for blood for the assay is not for such because of the presence of a pair of N-glycans on S. of and glycoforms using multiple 2013; PubMed Scopus Google Scholar). A is thus to aberrant cancer biomarker development in a clinical as as to the glycan in a method by a specific glycoform be quantitatively measured by using a and lectin this fucoform biomarkers through a case-control study in a sensitive and manner. the validation results as a a biomarkers that and HCC AFP or AFP-L3 is alone. To it is the that aberrant glycan are as an in vitro diagnostic multivariate index assay in the development of cancer cells were with carrying the human or for the using an to the The DNA for are in The was and by and lectin was at in an fetal serum and with and the were by the Taniguchi at the The human AFP was the and cells as were various participants at the with to The of was and by the with or were to the associated of HCC patients were and of were and then at for at for to and cellular were and at blood were and were for were on and The were in for or for lectin and antibodies were as and lectin and Lens culinaris lectin were to glycan with antibodies or were allowed to with and to an for RNA was cells using an and for of was as for was the total RNA using a and of was for A pair with of and was to the level of the human oligonucleotides were by of oligonucleotides with oligonucleotides with and a T7 promoter in a of antibodies was with in under The antibodies were with the oligonucleotides at for and the was by with at for The was and following on a with a molecular of was the of or cells following using a with a molecular of For of targets in serum were with at and the were for of the or the serum was with of an and antibodies for at complex was on various lectin were extensively with of at The for lectin chromatography were either or as a form on lectin The glycoforms were for T7 and following extensive RNA were using a T7 RNA to the antibodies or were at in the presence of of T7 in of and either or were in in for with and as in were at in and on a using a microarray the were in a at for by for by for and The RNA were with a and and with on a microarray chip with a at for The were and then the were with and for and were in a The was measured using for AFP and alpha-2-macroglobulin (A2M) were and were to the were and to assay with for and were with including the of the and the under the The diagnostic were compared by the the and sensitivity and specificity that between and HCC were was lines of evidence indicate that a in is associated with and various diseases (1Christiansen M.N. Chik J. Lee L. Anugraham M. Abrahams J.L. Packer N.H. Cell surface protein glycosylation in cancer.Proteomics. 2014; 14: 525-546Crossref PubMed Scopus (370) Google Scholar, Ko J.H. Kim Y.S. and of using aberrant glycosylation as biomarkers for in 2011; PubMed Scopus Google Scholar, J. of aberrant PubMed Scopus Google Scholar). protein glycan is a process and thus the glycan are it is to and specific Because an aberrant glycoform be developed as a disease-specific a with high analytical sensitivity and specificity is in the biomarker development to an analytical method to biomarkers of with a specific glycan For antibodies were tagged with a with an DNA at the of in The IgG-type antibodies have a pair of N-glycans at the in the of the The are by following H. Li and of glycoproteins using and PubMed Scopus Google Scholar), and these in with a functional at the of an The oligonucleotides are of a pair of of has a T7 promoter and an The as a and is to an and the The for of targets is in the is with of blood or are with A complex is on a lectin through between glycans on an and a The is with an the and the of is to that of a glycoform of an a specific glycoform of an be the is as a for T7 to fluorescent The are and on a DNA microarray of a DNA to the of an and the of glycan N-glycans of an was with to functional were with either or with The was in the presence of was by an using The of glycan was by The was on a with a and the presence of the was by The was in the and not in the The was with AFP to form an and the complex was on a under the as that in B. The lectin indicates the of the complex on a The of either or with various was including and The lectin were by and the antibodies were by an in the indicates the ratio of antibodies to the after of with are of with was that this method be with multiplexed and highly sensitive of targeted by using a of antibodies. in the complex be through An analytical validation of method with an with oligonucleotides with The of a comprising with between and with The was to by as by with The indicates the presence of a with the of an was with oligonucleotides with a be by between that the of significant to the of For a targeted glycoform of a biomarker to be by RNA that are the DNA as a it is that that an be the To this a test was where the was on a and the presence of the was investigated in in was not in the that the be by is that the were by in the of the the and of In the complex was on a results indicate that glycans of not of the in the the that a specific be the of examined were by the because it is to the of that are To this of antibodies were tagged with oligonucleotides and their were was that the glycan including the were to including and of antibodies with and of the antibodies were in the with was that exists a of antibodies that a certain glycoform that is not by DNA However, with the corresponding the glycoforms of the could be and thus a of a allowed antibodies to be to for Because and antibodies are not for glycan the be for analytical and to an has a that production of by a with a T7 in the presence of A of were in the absence of this to be a of oligonucleotides that been to antibodies and with could the DNA and thus in the on a DNA microarray chip The was to be RNA by The production of was with with and after of The T7 was at for the To test the of lines of with or of were by either of or a RNA for the indicated the of lines For a was the the for and cells were and compared with the level of cells proteins were of and and protein was that the of was as by an An of was to and the proteins were and was by an the fucoform of could not be in these In method using could the under the conditions as for the and the measured levels were to the the In to high specificity was in the where the RNA of was on an the evidence in that the of method be in a that the level of could be between the and A of protein glycosylation is that the level of a specific glycoform on the of etc. in the glycan level is not to be by and to be a subset of proteins that an or even level of in the compared with the Because these to be for improved test and of a study with cells in with the A using the of AFP was in lines and on an chromatography The and were in the and compared the analytical sensitivity of method with that of with a on a of protein were to with an and on a The were with a with a fluorescent the cells was by and a was at of total the was in of total proteins was for measurement of the fucoform of An indicates an in the analytical sensitivity An analytical sensitivity of method was by an using a serum for of a glycoform were compared including test using as test using and method a analytical sensitivity compared with the tests using and to be to this analytical because of high analytical method was to be to the measurement of a tests using and high is to the and a test for in an of of that method is for a of an specific glycoform of a biomarker in To method to the of a fucoform of a a was and RNA in an with an DNA The of the were to and the RNA were The fluorescent of the RNA was measured on a DNA microarray chip at a was with between the ratio and the ratio of at and in a ratio of to were in of and results that and were on the disease in the to method to clinical validation of the biomarker candidates. with a DNA were to of or antibodies and a of the antibodies was with their in and HCC the on an RNA were using (HCC) or the oligonucleotides as a and the ratio of was measured on a microarray as in The results a ratio for biomarker in HCC The of the were the as the in that the level of a fucoform be a by the total of biomarker a ratio of the fucoform be by the following and indicate the fucoform and total of the biomarker in or hepatocellular carcinoma (HCC) in the the fucoform ratio was by the the This be that the fucoform ratio is by the This is in that a in in was not in This a that a fucoform to by an ratio was to a of such for and thus to specificity of the of a the total and the fucoform for and in a clinical in a validation with of and HCC The are of and with and a of were and the of subjects was to be between and HCC. are provided in I. In this case-control study, of for liver diseases in the blood tests and developed diseases were and for are in the fucoform ratio for and the fucoform The for are in and the fucoform for AFP were by on microarray and tests through The fucoform ratio an as liver disease conditions to hepatocellular In was a fucoform for HCC, as by the for and of the in a An in vitro diagnosis multivariate index assay is as a test that the of multiple using an to a that is for use in the diagnosis of disease or or in the or of of and for and In 2012; Google Scholar). are the the is based on the that multiple biomarkers be and this diagnostic for HCC applied to of the fucoform for and was and were the of the to the diagnostic in of and for and The diagnostic was the in a for the of the clinical The index in the of and the of sensitivity and specificity of and The a improved diagnostic for the in this case-control study, compared with the diagnostic for the AFP level or AFP-L3 The under was for the fucoform was the AFP-L3 and AFP level tests The and are compared with of in and a that a of the in the indicates improved diagnostic for HCC with sensitivity and specificity of and compared with by either AFP level or AFP-L3 alone. improved sensitivity was by the panel of biomarkers AFP-L3 with in sensitivity and specificity were the test with results subjects The to be in an test that the be and applied to diagnostic for HCC. For an test comprising and and HCC an and measured the fucoform ratio and protein levels using the method and applied the and in to the test to the for the biomarkers and the The of this method to the test a diagnostic to that of the a sensitivity of and a specificity of with an of the use of of biomarkers a the of the in the diagnostic in terms of specificity and that method was and for to of index for AFP and in a the results indicate that method a and sensitive of the levels of specific glycoforms of The analytical of method was by the clinical of the for HCC in a case-control The the fucoform level of and improved discriminatory power the diagnostic at Aberrant protein glycosylation has been cancer development and progression and the of aberrant glycosylation have been in functional (2Kim Y.S. Hwang S.Y. Kang H.Y. Sohn H. Oh S. Kim J.Y. Kim C.H. Jeon J.H. Lee J.M. Kang H.A. Miyoshi E. Taniguchi N. Yoo H.S. Ko J.H. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1.Mol. Cell. Proteomics. 2008; 7: 1-14Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar, S. Miyoshi E. Ko J.H. K. S. K. Taniguchi N. of N-acetylglucosaminyltransferase V is to and of by Full Text Full Text PDF PubMed Scopus Google Scholar, Lee I. M. M. Aberrant of and Google Scholar, Lee I. M. M. N-acetylglucosaminyltransferase V levels and Full Text Full Text PDF PubMed Scopus Google Scholar). of the is the role of aberrant glycans of tissue inhibitor of of colon cancer cells (2Kim Y.S. Hwang S.Y. Kang H.Y. Sohn H. Oh S. Kim J.Y. Kim C.H. Jeon J.H. Lee J.M. Kang H.A. Miyoshi E. Taniguchi N. Yoo H.S. Ko J.H. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1.Mol. Cell. Proteomics. 2008; 7: 1-14Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar). The by play an role in the tissue inhibitor of interactions, in and potential in colon the functional role of aberrant glycosylation in have to glycoforms as cancer biomarkers for various clinical the of this progress has not been because of the absence of an efficient validation method that sensitive of aberrant with multiplexed and analytical analytical be to by the with various of However, is a in that antibodies as a have a pair of N-glycans S. of and glycoforms using multiple 2013; PubMed Scopus Google and that lectin to the with to the have been H. Lee in a 2012; PubMed Scopus (34) Google Scholar, Wu J. P. S. method for of to PubMed Scopus Google Scholar, S. T. D. D. D. D. of glycan on proteins by 4: PubMed Scopus Google Scholar), and are for various has been to N-glycans an to the is N-glycans of an is located a pair of and thus a of conditions using following the process it the of an The of to the by However, the is an based on or chromatography be to the A significant of of antibodies could the and the of not be because of conditions of low of N-glycans using are to the were not proven for various the method was applied under conditions to the of for such as through a and be to and a as in However, this method not to be sensitive to a specific glycoform of In particular, it was to be even to the method to glycan biomarkers in serum or that a high of proteins and with the method analytical was for biomarkers and and that method be applied to the and validation of various aberrant of aberrant glycosylation-targeted biomarker development is to of as by N. biomarker and the and to clinical PubMed Scopus Google including and and validation is through analytical by biomarkers are a of biomarker by a high the the validation be by a in a manner. method is to and such as method is to be to in a of antibodies be to biomarker diagnostic are for diagnosis and of HCC, and be including and blood AFP has been the biomarker for HCC, because of the low sensitivity of the biomarker of the for the of not the of the AFP test for HCC for patients J. M. for the of of hepatocellular carcinoma: an 2011; PubMed Scopus Google Scholar). an of has been as a to the clinical that are for HCC patients with low AFP serum level L. F. S. F. M. of Lens culinaris of alpha-fetoprotein and or in as biomarkers for hepatocellular 2009; 7: Full Text Full Text PDF PubMed Scopus Google Scholar, K. Takase K. Tameda Y. M. Y. T. A clinical study of alpha-fetoprotein as an of hepatocellular carcinoma in the of PubMed Google Scholar). However, to the of AFP-L3% the use of AFP alone. a is that the ratio be in risk with the total AFP level test Z. Wang Y. D. J.M. D. J. D. S. M. and alpha-fetoprotein in hepatocellular 2009; Full Text Full Text PDF PubMed Scopus Google Scholar). Because it is widely that total AFP level and AFP-L3% are between and HCC of sensitivity and specificity between case-control not the is between tests a case-control method of the diagnostic of the tests using either total AFP or fuco-biomarkers of hemopexin, and The was that the the biomarkers be for improved diagnosis and of HCC. be that study is in that was of and the was the of the biomarker as an vitro diagnostic multivariate index that not between and is based on the test results of multiple biomarkers and their to a or of of the of the by an index by the be improved compared with a biomarker as in the blood test L.G. S. I. L. Zhang Z. of a multivariate index assay in the preoperative of 2011; PubMed Scopus Google Scholar). Because the the not or it in the of results this that be the process of in and the process be based on a and Z. An in vitro diagnostic multivariate index assay for the power of multiple 2012; Google Scholar). The was and evidence in this validation study and this as a of the assay of However, that the in be with clinical with through a In particular, it is to that is to that be on with as a to the of cancer PubMed Scopus Google Scholar). In this method validation through of clinical that of and is to test a discriminatory power for diagnosis and in such clinical Z. An in vitro diagnostic multivariate index assay for the power of multiple 2012; Google Scholar). The of method is based on of a of a specific glycoform between and test This a with or the of of serum with serum levels of and that to the for subjects C. alpha-fetoprotein levels in human a highly specific PubMed Scopus Google Scholar, a review of and the role in Acta. PubMed Scopus Google Scholar, M. of alpha and to the clinical of J. Full Text PDF PubMed Scopus Google Scholar), and as a a the or such as the of or and as a to the of cancer PubMed Scopus Google Scholar, to and of research molecular roles of and study Full Text Full Text PDF PubMed Scopus Google Scholar). For this it be of to a that be applied to method through method it to various disease-specific glycan in various in a highly sensitive and manner. This be in to biomarker development in aberrant glycoforms are targeted and that to various facilitate the development of aberrant a of research that is with Lens culinaris lectin lectin alpha-2-macroglobulin V hepatocellular carcinoma in vitro diagnostic multivariate index

References

23